Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases

References

• Sung H, Ferlay J, Siegel RL., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Shin I. HER2 signaling in breast cancer. Adv Exp Med Biol. 2021;1187:53–79.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Goodwin PJ. Breast cancer survivorship: where are we today. Adv Exp Med Biol. 2015;862:1–8.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer. 2021;124(1):142–155. doi:10.1038/s41416-020-01175-y
   PubMed Web of Science ®Google Scholar
• He DJ, Yu DQ, Wang QM, et al. Breast cancer subtypes and mortality of breast cancer patients with brain metastasis at diagnosis: a population-based study. Inquiry. 2021;58:469580211055636. doi:10.1177/00469580211055636
   PubMed Web of Science ®Google Scholar
• Tarantino P, Prat A, Curigliano G. New anti-HER2 agents for brain metastasis: histology-agnostic weapons. Breast Cancer Res Treat. 2021;185(3):879–881. doi:10.1007/s10549-020-05982-y
   PubMed Web of Science ®Google Scholar
• Zahid KF, Kumar S, Al-Bimani K, et al. Outcome of Omani women with breast cancer-associated brain metastases experience from a university hospital. Oman Med J. 2019;34(5):412–419. doi:10.5001/omj.2019.76
   PubMedGoogle Scholar
• Corti C, Antonarelli G, Criscitiello C, et al. Targeting brain metastases in breast cancer. Cancer Treat Rev. 2022;103:102324. doi:10.1016/j.ctrv.2021.102324
   PubMed Web of Science ®Google Scholar
• Gobbini E, Ezzalfani M, Dieras V, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018;96:17–24. doi:10.1016/j.ejca.2018.03.015
   PubMed Web of Science ®Google Scholar
• Costa R, Carneiro BA, Wainwright DA, et al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2017;28(1):44–56. doi:10.1093/annonc/mdw532
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–4843. doi:10.1158/1078-0432.CCR-10-2962
   PubMed Web of Science ®Google Scholar
• Gullhaug A, Hjermstad MJ, Yri O, Svestad JG, Aass N, Johansen S. Use of radiotherapy in breast cancer patients with brain metastases: a retrospective 11-year single center study. J Med Imaging Radiat Sci. 2021;52(2):214–222. doi:10.1016/j.jmir.2021.01.002
   PubMed Web of Science ®Google Scholar
• Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-brain radiotherapy for brain metastases: evolution or revolution. J Clin Oncol. 2018;36(5):483–491. doi:10.1200/JCO.2017.75.9589
   PubMed Web of Science ®Google Scholar
• Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol. 2010;75(2):110–121. doi:10.1016/j.critrevonc.2009.11.003
   PubMed Web of Science ®Google Scholar
• Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for brain metastases: changing practice patterns and disparities in the United States. J Natl Compr Canc Netw. 2017;15(12):1494–1502. doi:10.6004/jnccn.2017.7003
   PubMed Web of Science ®Google Scholar
• Akagunduz OO, Yilmaz SG, Tavlayan E, Baris ME, Afrashi F, Esassolak M. Radiation-induced ocular surface disorders and retinopathy: ocular structures and radiation dose-volume effect. Cancer Res Treat. 2022;54(2):417–423. doi:10.4143/crt.2021.575
   PubMed Web of Science ®Google Scholar
• Masucci GL. Hypofractionated radiation therapy for large brain metastases. Front Oncol. 2018;8:379. doi:10.3389/fonc.2018.00379
   PubMed Web of Science ®Google Scholar
• Lin NU, Pegram M, Sahebjam S, et al. Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a Phase II study. J Clin Oncol. 2021;39(24):2667–2675. doi:10.1200/JCO.20.02822
   PubMed Web of Science ®Google Scholar
• Shah N, Mohammad AS, Saralkar P, et al. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. 2018;132:47–68. doi:10.1016/j.phrs.2018.03.021
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. doi:10.1056/NEJMoa064320
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Mills MN, Walker C, Thawani C, et al. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021;21(1):223. doi:10.1186/s12885-021-07971-w
   PubMed Web of Science ®Google Scholar
• Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, Phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, Phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/S1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar
• Kioutchoukova I, Lucke-Wold BP. Pyrotinib as a therapeutic for HER2-positive breast cancer. Transl Cancer Res. 2023;12(6):1376–1379. doi:10.21037/tcr-23-333
   PubMed Web of Science ®Google Scholar
• Kim JM, Miller JA, Kotecha R, et al. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol. 2017;133(2):357–368. doi:10.1007/s11060-017-2442-8
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang H, Zhou J, et al. Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study. Ann Transl Med. 2022;10(22):1228. doi:10.21037/atm-22-5352
   PubMedGoogle Scholar
• Ma X, Li Y, Zhao Z, et al. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis. Exp Biol Med. 2023;248(2):106–116.
   Web of Science ®Google Scholar
• Ording AG, Heide-Jørgensen U, Christiansen CF, Nørgaard M, Acquavella J, Sørensen HT. Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis. 2017;34(1):93–101. doi:10.1007/s10585-016-9824-8
   PubMed Web of Science ®Google Scholar
• Chan WL, Lam TC, Lam KO, Luk MY, Kai-Cheong RN, Kwong LD. Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review. Ther Adv Med Oncol. 2020;12:1758835920953729. doi:10.1177/1758835920953729
   Web of Science ®Google Scholar
• Kim JS, Kim IA. Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol. 2020;12:1758835920936117. doi:10.1177/1758835920936117
   Web of Science ®Google Scholar
• Chien AJ, Rugo HS. Tyrosine kinase inhibitors for human epidermal growth factor receptor 2-positive metastatic breast cancer: is personalizing therapy within reach. J Clin Oncol. 2017;35(27):3089–3091. doi:10.1200/JCO.2017.73.5670
   PubMed Web of Science ®Google Scholar
• Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in her2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, Phase II study. J Clin Oncol. 2019;37(29):2610–2619. doi:10.1200/JCO.19.00108
   PubMed Web of Science ®Google Scholar
• Yang H, Wang W. Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study. Am J Transl Res. 2021;13(9):10863–10870.
   PubMed Web of Science ®Google Scholar
• Gao M, Fu C, Li S, et al. The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: a multicenter study. Cancer Med. 2022;11(3):735–742. doi:10.1002/cam4.4481
   PubMed Web of Science ®Google Scholar
• Klaas E, Sung E, Azizi E, et al. Advanced breast cancer metastasized in the brain: treatment standards and innovations. J Cancer Metastasis Treat. 2023;9:23.
   Google Scholar
• Fauquette W, Amourette C, Dehouck MP, Diserbo M. Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res. 2012;1433:114–126. doi:10.1016/j.brainres.2011.11.022
   PubMed Web of Science ®Google Scholar
• Tian W, Hao S, Wang L, Chen Y, Li Z, Luo D. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients. Anticancer Drugs. 2022;33(1):e622–e627. doi:10.1097/CAD.0000000000001199
   PubMed Web of Science ®Google Scholar
• Mampre D, Mehkri Y, Rajkumar S, et al. Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches. Diagn Ther. 2022;1(1):25–38. doi:10.55976/dt.1202216523-36
   Google Scholar
• Anwar M, Chen Q, Ouyang D, et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data. Clin Cancer Res. 2021;27(16):4634–4641. doi:10.1158/1078-0432.CCR-21-0474
   PubMed Web of Science ®Google Scholar
• Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J Neurooncol. 2012;109(1):91–98. doi:10.1007/s11060-012-0868-6
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62. doi:10.1200/JCO.2016.69.1378
   PubMed Web of Science ®Google Scholar
• Hackshaw MD, Danysh HE, Henderson M, et al. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer. 2021;21(1):967. doi:10.1186/s12885-021-08708-5
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim JS, Kim IA. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. J Cancer Res Clin Oncol. 2018;144(9):1803–1816. doi:10.1007/s00432-018-2697-2
   PubMed Web of Science ®Google Scholar
• Klaas E, Mohamed S, Poe J, Reddy R, Dagra A, Lucke-Wold B. Innovative approaches for breast cancer metastasis to the brain. Arch Med Case Rep Case Study. 2022;6(4):147. doi:10.31579/2692-9392/147
   Google Scholar